ArticleHepatology international2025
Global, regional, and national epidemiology of hepatoblastoma in children from 1990 to 2021: a trend analysis.
Article in Hepatology international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Parental and childhood exposures and the risk of retinoblastoma, hepatoblastoma, and germ cell, bone, and soft tissue tumors in children: a systematic review and meta-analysis.Frontiers in oncology · 2026Pooled it
- [Surgical management of children with liver tumors in Germany : Evidence, care structures and future perspectives].Chirurgie (Heidelberg, Germany) · 2026Review
- Integrative bioinformatics analysis identifies ubiquitin-related genes and their regulatory networks in hepatoblastoma.Discover oncology · 2026Article
- Burden of liver cancer from 1990 to 2021 and modelled projection to 2040: insights from the global burden of disease study 2021.Frontiers in oncology · 2026Article
- Children's hepatoblastoma: gender and infant age demand focus in the global burden of disease study 2021.Hepatology international · 2025Article
- Global trends and regional differences of hepatoblastoma: a systematic analysis and predictions to 2035 based on the global burden of disease study 2021.BMC public health · 2025Article
- Global Burden of Hepatoblastoma From 1990 to 2021 and Projection to 2030.Cancer medicine · 2025Article
- Article
- Lipid metabolism abnormalities in pediatric abdominal solid malignant tumors: a comprehensive review.Frontiers in pediatrics · 2025Review
- Asian Burden of Liver Cancer 1990-2021 and Predictions to 2040: An Analysis of the Global Burden of Disease Study 2021.Cancer control : journal of the Moffitt Cancer CenterArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
background and purposeHepatoblastoma is the most common primary liver cancer in children, yet comprehensive understanding of its epidemiology is limited globally. We aimed to estimate the global trend of hepatoblastoma in children from 1990 to 2021.
methodsWe collected data on hepatoblastoma in children aged 0 to 10 years from 1990 to 2021, derived from Global Burden of Disease (GBD) 2021. Three disease burden indicators, including incidence, mortality, and disability-adjusted life-years (DALYs), were studied. The corresponding average annual percentage changes (AAPCs) were used to explore the temporal trends of hepatoblastoma.
resultsIn 2021, hepatoblastoma accounted for 4048 incident cases, 2416 deaths, and 213,478 DALYs globally. Incidence, mortality, and DALYs of hepatoblastoma decreased significantly from 1990 to 2021, with AAPCs of -2.12, -2.53, and -2.53. The highest incidence of hepatoblastoma was observed among those aged < 28 days in 2021 (2.57 per 100,000 individuals). Only high-income region showed an upward trend in incidence from 1990 to 2021, with an AAPC of 0.57. The Western Pacific region had the fastest decrease in the incidence, mortality, and DALY rate of hepatoblastoma. Human development level (HDI) was positively associated with the AAPC in incidence from 1990 to 2021, while HDI was negatively associated with the incidence, mortality, and DALY rate of hepatoblastoma in 2021.
conclusionGlobal efforts over the past 3 decades have substantially decreased the disease burden of hepatoblastoma in children. However, increases in the incidence of hepatoblastoma in high-income region merit attention. The highest disease burden of hepatoblastoma was observed in the neonatal period. Improved understanding of hepatoblastoma epidemiology may facilitate prevention and management.
Indexed as
Identifiers
39580764What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.